KRAS and neoplasm: In our cohort, the molecular evaluation of RAS mutational status in tumor tissue samples, performed by NGS, confirmed a low frequency of both KRAS [29] and NRAS mutations in mCRC patients, which is in agreement with the data reported in the literature for this type of tumor (1–5% for mCRC) [30].